Recent News
Multiple Genetic Variants Increase Mesothelioma Risk
The term “high-risk predisposition,” is a well-known term in the cancer world that means a person could have certain genetic factors or other factors that places him or her at…
Mesothelioma Patients Receive Zoledronic Acid as Treatment
Known as a bisphosphonate, zoledronic acid is typically used for bone diseases such as osteoporosis, and to treat high calcium levels in the blood that can lead to other health…
Adjuvant Pembrolizumab After Radiation Therapy for Lung-Intact Malignant Pleural Mesothelioma
Purpose: The goal of this clinical research study is to assess the safety of pembrolizumab (also called MK-3475) after radiation therapy (with or without surgery and/or chemotherapy) in patients with MPM.
Time Increases Risk for Mesothelioma, Study Finds
Asbestos-related illnesses such as mesothelioma and asbestosis have been known to develop over a period of decades, affecting people years and years since their last exposure. Many studies over the…
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma
Purpose: This randomized phase I/II trial is studying the side effects and best dose of cediranib maleate when given together with pemetrexed disodium and cisplatin and to see how well it works in treating patients with malignant pleural mesothelioma. Drugs used in chemotherapy, pemetrexed disodium and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cediranib maleate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving pemetrexed disodium and cisplatin together with cediranib maleate may kill more tumor cells.
Giving Cediranib Another Chance
A Phase I study for cediranib, a VEGFR/PDGFR kinase inhibitor, showed promising results in shrinking tumor size and increasing survival rates for those suffering from malignant pleural mesothelioma. This is…
Calretinin More Effective Than Mesothelin in Detecting Mesothelioma Early
Mesothelioma is a rare and aggressive cancer that is difficult to diagnose because symptoms often mimic other diseases such as pulmonary fibrosis or lung cancer. Pathology reports and biopsies help…
Survival Rates Based Upon Subtypes of Mesothelioma
A recent study published in the British Journal of Cancer compared survival rates of mesothelioma patients that received their diagnosis through either cytological or by histological method for those with…
Phase I Clinical Trial Underway for CAR T-cell Therapy
A Phase I clinical trial for an immunotherapy treatment for malignant pleural mesothelioma and non-small cell lung cancer (NSCLC) is currently underway at the University of Pennsylvania in Philadelphia. Immunotherapy…
Poziotinib in EGFR Exon 20 Mutant Advanced Non-Small Cell Lung Cancer (NSCLC)
Purpose:The goal of this clinical research study is to learn if poziotinib can help to control EGFR-positive non-small cell lung cancer (NSCLC) that is locally advanced or metastatic (has spread). EGFR-positive NSCLC means that there is a mutation (a type of genetic change) on the EGFR gene.
The safety of poziotinib will also be studied
